share_log

复星医药(600196.SH):控股子公司获药品临床试验批准

Fosun Pharmaceuticals (600196.SH): Holding subsidiary approved for drug clinical trials

Gelonghui Finance ·  Apr 17 04:37

Gelonghui, April 17 | Fosun Pharmaceutical (600196.SH) announced that its holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its holding subsidiary recently received approval from the National Drug Administration to conduct clinical trials with HLX53 (i.e. anti-Tigit FC fusion protein) combined with Hans form (i.e. slulizumab injection) and Hanbetai (i.e. bevacizumab injection) for first-line treatment of locally advanced or metastatic hepatocellular carcinoma (HCC). Fu Hong Hanlin plans to conduct phase II clinical trials of this treatment plan in China (excluding Hong Kong, Macao and Taiwan regions) when conditions are met.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment